Affimed(AFMD) - 2023 Q1 - Quarterly Report

Exhibit 99.1 PRESS RELEASE Affimed Reports 2022 Financial Results and Operational Progress • AFM13 combination with AB-101 NK cells: On track for IND filing in H1 2023 and initiation of clinical study in 2023 • AFM13 monotherapy REDIRECT data: Oral presentation at the AACR annual meeting • AFM24: Data from the three ongoing studies expected to be presented at scientific conferences in Q2 or Q3 of 2023 • AFM28: Clinical phase 1 study is open and recruiting; clinical trial applications now approved in four Eu ...